InSite Vision has earned $15 million for future royalties of Besivance, its pink-eye antibacterial eye drop, according to a San Francisco Business Times report.
Bess Royalty and SWK Funding are expected to pay an additional $1 million to InSite if Besivance sales goals are met by February 2014.
Besivance has been FDA approved since 2009 and is sold worldwide by Bausch + Lomb.
More Articles on Ophthalmology:
Devers Eye Institute Offers Corneal Crosslinking
Dr. Mary Green Honored as Sightpath Top Surgeon
IRIDEX, Peregrine Surgical Partner
Bess Royalty and SWK Funding are expected to pay an additional $1 million to InSite if Besivance sales goals are met by February 2014.
Besivance has been FDA approved since 2009 and is sold worldwide by Bausch + Lomb.
More Articles on Ophthalmology:
Devers Eye Institute Offers Corneal Crosslinking
Dr. Mary Green Honored as Sightpath Top Surgeon
IRIDEX, Peregrine Surgical Partner